3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
29
Recruiting
8
Terminated
5
Withdrawn
3
Unknown
3
No longer available
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
3
Gynecologic
2
Classical hematology
1
Conditions
Sarcoma
3
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Chondrosarcoma
1
Bone Neoplasms
1
Interventions
Doxorubicin
25
Radiotherapy
16
apatinib
15
Cyclophosphamide
15
Ifosfamide
13
anlotinib
12
camrelizumab
10
Temozolomide
9
Imatinib Mesylate
9
Vincristine
8
Surgical Procedures, Operative
7
Neoadjuvant Therapy
7
Methotrexate
7
Drug Therapy
7
Dactinomycin
5
Blood Specimen Collection
5
fludarabine phosphate
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
Etoposide
4
Docetaxel
4
Carboplatin
4
toripalimab
3
pembrolizumab
3
Trabectedin
3
Topotecan
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Nivolumab
3
Melphalan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
Trabectedin
×
Sarcoma
×
Clear all
NCT03985722
2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1
Unknown
28 enrolled
NCT05131386
2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
85 enrolled
NCT02359474
2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2
Unknown
120 enrolled